Zilico end of year review with Sameer Kothari

Monday 23rd December 2019

Looking Back at 2019 with Sameer Kothari, CEO of Zilico Ltd.

It's been another fantastic year for Zilico; we have seen further adoption of ZedScan™ in UK and Europe and have expanded our office and field teams, enhancing our customer support. Our strategic partnership with Maxhealth Medical Group continues to grow, with NMPA progressing to bring ZedScan to the China market. Our US plans are also moving forward, having had our first official meeting with the FDA. The grant award from SBRI in early 2019 has enabled us to further develop our EIS technology and create a prototype device for oral cancer detection, ready for clinical trials, adding another dimension to our EIS portfolio. Our achievements have again received industry recognition, with Zilico awarded for our strong NHS partnerships. We were also proud to feature in The Times Future North, Life Science edition in March and the recent ABHI and ITN Productions ‘Transforming Healthcare’ film.

Continued Adoption of ZedScan

In 2019, NHS Tayside became the second trust in Scotland to introduce ZedScan into their colposcopy services at Ninewells Hospital, Dundee. Across Europe, a second hospital in Finland, Oulu University Hospital, responsible for healthcare in the North of the country, adopted ZedScan to give clinicians additional diagnostic information to enable them to better manage their patients. ZedScan is now in routine use at Alexandra University Hospital, Athens, following a successful service evaluation, making it the first adoption in Greece. With ZedScan now in routine use at Aberdeen Royal Infirmary, University Hospitals North Midlands (Stoke & Stafford), Central Manchester University Hospitals (St Mary’s & Trafford), Sheffield Teaching Hospitals NHS Foundation Trust, Birmingham Women’s Hospital, Helsinki University Hospital and Wroclaw University Hospital, Poland, we are excited to see this growth continue in 2020, supporting parity of care for all women referred to colposcopy.

The Introduction of Primary HPV Screening in the UK

March saw the launch of the first ever national campaign by PHE to raise awareness of cervical cancer and HPV. The campaign was aimed at informing women about the changes to the screening programme and the importance of attending their cervical screening. When we attended the BSCCP conference in May, this was also a leading topic at the congress, with particular focus on patient experience. There was also the welcome announcement in 2019/20 that boys will now be vaccinated against HR-HPV in the UK. Throughout the year we have been highlighting the impact of the HPV vaccinated population entering the screening programme and the importance of patient experience, informing and educating clinicians through our User Group programme and focus days.

Provision of Colposcopy Services in Remote Areas of the UK

The Gilbert Bain Hospital, in the Shetland Islands which sees around 120 women a year referred to colposcopy, have also incorporated ZedScan into their services, reflecting the ongoing uptake of the device across Scotland, with nurses from Aberdeen travelling to provide colposcopy with ZedScan there, preventing patients having to travel to the mainland. In November, we provided colposcopy services to women in the Falkland Islands as part of a remote clinical access programme. Zilico Training Manager and Nurse Colposcopist, Alison Roberts RGN, travelled to the Falkland Islands to carry out colposcopy examinations with ZedScan at King Edward VII Memorial Hospital, Stanley. For women living in the Falklands this means avoidance of travel to the UK for colposcopy examination and/or treatment, which reduces stress for the women referred and delivers cost benefits for the health services.

Partnership with Jo’s Cervical Cancer Trust

In June, we proudly announced our corporate partnership with Jo’s. Through this partnership, alongside education around cervical screening and signposting to the charity support services, Zilico will make a donation to the charity for every ZedScan single-use EIS sensor sold in the UK. Our contributions will help to support Jo’s charitable activities supporting those affected by cervical cancer.

Looking forward to 2020

In the coming year, as we enter a new era of primary HPV, we will continue to educate and inform on the changing patient profiles and the challenges this brings for visual colposcopy. We will drive wider adoption of ZedScan across the UK, Europe and beyond to enable clinicians to make more informed decisions at a patient’s first visit for better outcomes and improved health economics. Thank you for being a part of our journey, we look forward to another fantastic year.